Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity
about
Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase.Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats.A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in miceLive bacterial vaccines--a review and identification of potential hazards.Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B.Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.Bacteria-mediated DNA transfer in gene therapy and vaccination.Attenuated salmonella and Shigella as carriers for DNA vaccines.Prospects for developing an effective vaccine against ocular herpes simplex virus infection.Intranasal delivery of vaccines against HIV.Optimization and delivery of plasmid DNA for vaccination.Use of attenuated bacteria as delivery vectors for DNA vaccines.Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.Mucosal vaccine delivery: Current state and a pediatric perspectiveConstruction of recombinant lactobacilli expressing the core neutralizing epitope (COE) of porcine epidemic diarrhea virus and a fusion protein consisting of COE and Escherichia coli heat-labile enterotoxin B, and comparison of the immune responseLive Bacterial Vectors-A Promising DNA Vaccine Delivery System.
P2860
Q30373761-916948BD-3E82-4222-94B5-1C34AE642349Q30373857-1912FAC2-6917-4295-B282-0FCAC196BF5FQ34098868-CCE08B6C-2FC5-4BA4-BA0E-FD5310CF7990Q34348269-93EF85C2-7F5F-42B5-AA5B-02DFCEF0D05EQ34545911-EEB4DB25-230B-43FA-8E27-CA8D149E8C18Q34974711-03B68603-CB61-48DC-AB18-6EFA2D92D8C1Q35138652-DE95FC78-5333-4D13-9564-845D87FC9475Q35142923-9388F774-1514-4AAC-A402-9A758426B1C6Q35681498-27F3327D-4591-446A-94BF-45985BF3F51DQ35809245-9A668FFF-6B5B-4B93-B62D-EE4BC969F106Q36311038-0D61C009-B9E9-4D35-8FE2-947AACD5E560Q36409054-F6CC995C-1E69-4E46-A8FB-E33C3577EA78Q36690285-BF3592AC-29FE-4268-B5A6-347F1BA223C6Q36728805-A16DE94B-F5AD-40C4-B4F1-6F28626D63C8Q37259634-4D92486B-7E37-447E-A969-DFCDB82324D6Q37511451-DCED74C3-039B-4C11-B92D-D5422A4A1A39Q38727453-36707856-7A0D-4D5F-B077-FCCB3C93C626Q42286868-C7AB5290-629A-4E63-8577-26281A1A3B32Q52640510-707E8A39-8C4E-43D2-A9AC-563701CD2151
P2860
Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Vaccination with a Shigella DN ...... antiviral protective immunity
@ast
Vaccination with a Shigella DN ...... antiviral protective immunity
@en
type
label
Vaccination with a Shigella DN ...... antiviral protective immunity
@ast
Vaccination with a Shigella DN ...... antiviral protective immunity
@en
prefLabel
Vaccination with a Shigella DN ...... antiviral protective immunity
@ast
Vaccination with a Shigella DN ...... antiviral protective immunity
@en
P2860
P1433
P1476
Vaccination with a Shigella DN ...... antiviral protective immunity
@en
P2093
P2860
P304
P356
10.1128/JVI.75.20.9665-9670.2001
P577
2001-10-01T00:00:00Z